title: Serum pentraxin-3 levels are associated with the severity of metabolic syndrome.
abstract: OBJECTIVE
  The aim of the present study was to assess the association between the level of pentraxin-3 (PTX-3) and the severity of metabolic syndrome (MS).
  
  
  METHODS
  One hundred and two patients with MS and 101 consecutive age- and sex-matched control subjects were included in the study. The MS patients were classified into three groups based on the number of MS criteria, i.e. group 1: patients with 3 MS criteria, group 2: patients with 4 MS criteria, and group 3: patients with 5 MS criteria. Serum PTX-3 and high-sensitivity C-reactive protein (hs-CRP) levels were measured.
  
  
  RESULTS
  Group 1 had higher PTX-3 levels compared to the control group (0.58 ± 0.11 ng/ml vs. 0.36 ± 0.15 ng/ml, p < 0.001). PTX-3 levels were higher in group 3 than in both group 1 (0.90 ± 0.06 ng/ml vs. 0.58 ± 0.11 ng/ml, p < 0.001) and group 2 (0.90 ± 0.06 ng/ml vs. 0.63 ± 0.12 ng/ml, p < 0.001). Group 3, however, had higher hs-CRP levels than both group 1 (1.89 ± 0.45 mg/dl vs. 1.40 ± 0.44 mg/dl, p = 0.007) and group 2 (1.89 ± 0.45 mg/dl vs. 1.47 ± 0.58 mg/dl, p = 0.01). The control group had lower hs-CRP levels than group 1 (0.81 ± 0.47 mg/dl vs. 1.40 ± 0.44 mg/dl, p < 0.001) and group 2 (0.81 ± 0.47 mg/dl vs. 1.47 ± 0.58 mg/dl, p < 0.001). Serum PTX-3 levels correlated with serum hs-CRP levels (r = 0.49, p < 0.001).
  
  
  CONCLUSIONS
  PTX-3, a novel inflammatory marker, was found to be associated with the severity of MS.
authors.affiliation: Department of Cardiology, Mustafa Kemal University, Tayfur Ata Sokmen Medical School, Antakya, Turkey. mfkarakas@hotmail.com
authors.forename: Mehmet Fatih
authors.initials: MF
authors.lastname: Karakas
authors.forename: Eyup
authors.initials: E
authors.lastname: Buyukkaya
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kurt
authors.forename: Sedat
authors.initials: S
authors.lastname: Motor
authors.forename: Adnan Burak
authors.initials: AB
authors.lastname: Akcay
authors.forename: Esra
authors.initials: E
authors.lastname: Karakas
authors.forename: Şule
authors.initials: Ş
authors.lastname: Buyukkaya
authors.forename: Nihat
authors.initials: N
authors.lastname: Sen
mesh_terms: D000328:Adult; D015415:Biomarkers; D015992:Body Mass Index; D001837:Body Weights and Measures; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000453:epidemiology; D008875:Middle Aged; D062072:Patient Acuity; D011446:Prospective Studies; D011897:Random Allocation; D000683:Serum Amyloid P-Component / Q000032:analysis*; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D000099153:Pentraxins